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Vitamin D (VitD), although originally described as an essential hormone for bone and mineral homeostasis, appears to have
an active role in regulating speciﬁc facets of human immunity. Indeed, VitD has been shown to have signiﬁcant eﬀects on
cytokine production and lymphocyte proliferation. Evidence that VitD aﬀects clearance of selected pathogens is supported by
epidemiological and clinical data, while its coadministration with inﬂuenza vaccine in mice enhanced both mucosal and systemic
antibody responses. This paper aims to examine how VitD may contribute to limiting the burden of inﬂuenza infection in the
aging and aged adults, a population in which this burden remains considerable. Furthermore, we discuss how VitD status may play
a role in host resistance to inﬂuenza virus and inﬂuence the immunogenicity of the inﬂuenza vaccines currently licensed for adults
aged 65 years or over by its eﬀects on innate and adaptive immunities.
1.Introduction
Worldwide, naturally occurring dietary sources of vitamin D
(VitD) are limited, and food fortiﬁcation is often optional,
inconsistent, inadequate, or nonexistent [1]. In common
with most population subgroups, except infants, adults
aged 65 years old or over depend on sunlight for most of
their VitD requirements [1, 2]. However, many variables
inﬂuence the amount of ultraviolet (UV) B (290–315mm)
radiation that reaches the skin and its eﬀectiveness. These
include time of day, latitude, altitude, clothing, sunscreen
use, pigmentation and age itself [3, 4]. Indeed, even regularly
exposedtosunlight,olderadultsproduce75%lesscutaneous
VitD than younger adults making them more prone to
develop VitD deﬁciency, deﬁned as a serum or plasma 25-
hydroxyvitamin D (25(OH)D) concentration lower than
10ng/mL (i.e., 25nmol/L) [4]. In our northern latitudes
(including Switzerland), between November and March,
there are insuﬃcient UV-B rays to produce VitD. Some re-
ports asserted that 15% of healthier community-dwelling
old adults remain VitD insuﬃcient even during summer-
time, while only 30% reached the desirable plasma levels
(>30ng/mL or 75nmol/L) at the end of the summer season
[5]. Moreover, recent studies have shown that, in the last 10
years alone, serum VitD levels fell on average by 20% [6].
Even though recent evidence suggested that inter-laboratory
variability may also contribute to the interpretation of this
estimate [7, 8], VitD deﬁciency is increasingly being recog-
nized as a worldwide epidemic [2, 9, 10]. This statement has
led to consider that most of the world’s adult population
will not be getting an amount of VitD suﬃcient to maintain
healthy bone mass and minimize risk of fracture and of falls
[2, 11]. In addition to these usual impacts on bone health,
calcium and phosphorus metabolism, decreased VitD status,
and/or dietary intakes of VitD have been demonstrated
to decrease muscle strength and to increase the risk of
type 2 diabetes, atherosclerosis, and neoplastic and immune
disorders such as type 1 diabetes mellitus and multiple
sclerosis [1, 2, 12]. These ﬁndings have led to suggest that
VitD could play a role in regulating speciﬁc facets of human2 Journal of Aging Research
immunity [12, 13]. This was reinforced by the fact that
the VitD receptor (VDR), the receptor that mediates all
known vitamin-related biological eﬀects, is widely expressed
on cells of the immune system (see Figure 1)[ 14–16]. This
paper will aim to examine how VitD may contribute to
limiting the burden of inﬂuenza infection in the aged adults,
a population in which this burden remains considerable.
Furthermore, considerations will be given on how VitD
status may play a role in host resistance to inﬂuenza virus
as well as inﬂuence the vaccine immunogenicity and this by
its eﬀects on both arms of the immune system (i.e., innate
and adaptive immunity).
2. Why Does Seasonal Inﬂuenza
Infection Remain a Considerable Burden in
the Elderly Population?
Worldwide, seasonal inﬂuenza infection continues having
a considerable impact. Annual estimates indicate that in-
ﬂuenza virus causes 3–5 million severe cases resulting in
250,000 to 350,000 deaths worldwide [18, 19]. The high-
est inﬂuenza infection prevalence occurs amongst older
adults especially those with chronic medical conditions or
immunological disorders. These are causal factors for the
increased mortality observed within these high-risk groups
[20]. However, mortality is just the tip of the iceberg in terms
of disease burden. Recent data demonstrated that inﬂuenza
can act as a trigger for functional decline leading to disability
in some aged individuals and also contributes to excessive
hospitalizations, medical visits, and antibiotic prescriptions
[21,22].Suchoutcomesrepresentanadditionalconsiderable
economic burden amounting to $87 billion each year in the
United States [23]. This burden is partly explained by the
age-related decline both in nonspeciﬁc and speciﬁc immune
responses leading, respectively, to a weaker host capacity to
resist inﬂuenza virus and to a less optimal immune response
to immunization.
2.1. The Nonimmune Speciﬁc Mechanisms That Facilitate
Inﬂuenza Infection. The respiratory tract represents the
primary site for the introduction and deposition of poten-
tially pathogenic microorganisms into the body including
inﬂuenza virus, and this is mainly through inspired air.
Defences of the respiratory tract involve both mechanical
factors, mucociliary escalator, receptor, and eﬀector mol-
ecules of the innate immune system [24]. One of the key
players of the defence system is the ciliated epithelium
lining the airway which acts through the physical removal
both by the ciliary clearance and the cough reﬂex. In
addition, the presence of broad-spectrum antimicrobial
agents in the mucus acting as surfactant, the presence of
phospholipase A2, the recruitmentof phagocyticcellsandan
inﬂammatory response all work in collaboration to defend
the airways [25]. Although, this sophisticated defence system
is weakened with advancing age and even in the absence
of overt lung disease [26–31], the intrathoracic dwell time
of inﬂuenza viruses is increased [29, 32] facilitating any
transepithelial migration of the viral particles. Advancing
age is, therefore, negatively associated with nasal, large and
small airways ciliary clearance. This is due to signiﬁcantly
slower ciliary beat frequency and longer mucociliary clear-
ance time [26, 27]. In addition, mechanical defences are
modiﬁed by the loss of lung elastic recoil together with
increased compliance of the intraparenchymal airway [28].
As demonstrated by experiments on aerosol transmission of
inﬂuenza virus the tidal breathing volume declines in the
aged individuals [31]. Those people often show impaired
ventilation function (measured by the FEV1 expressed as a
percentage of the volume predicted) which may be due in
parttodecreasedrespiratorymusclestrengthleadingtoaless
forceful coughing [29]. Complementarily, the sensitivity of
cough reﬂex is also decreased throughout all the nasosinusal
andtracheobronchialtree[30].Evenifthereisnoevidenceof
changes in the cells producing surfactant and modiﬁcations
of its composition, aged individuals have been found to
be subject to a chronic low-grade inﬂammation which re-
sembles to the one observed in COPD patients. However,
similarities are restricted only to qualitative aspects and not
quantitative [33]. As the primary contact of pathogens with
the adaptive immune system is via the antigen-presenting
cells (APCs), the age-related decline in the numbers of these
cells contributes to severely impact strategies for coping with
inﬂuenza. Further impact on the defense against inﬂuenza
may follow because of alterations in the response to toll-
like receptor (TLR) ligands. In a recent study, Panda et al.
found substantial decreases in older compared with young
individuals concerning TNF-α, IL-6, and/or IL-12 (p40)
production in myeloid dendritic cells in response to TLR1/2,
TLR2/6, TLR3, TLR5, and TLR8 engagement, as well as
tumor necrosis factor (TNF)α and interferon (IFN)α pro-
duction in plasmacytoid dendritic cells in response to TLR7
andTLR9engagement[34].Authorsalsofoundhigherintra-
cellular cytokine production in the absence of TLR ligand
stimulation by APCs in older compared with younger coun-
terparts, suggesting some dysfunction in the regulation of
cytokine production. Moreover, they showed a strong asso-
ciation between poor antibody responses to inﬂuenza im-
munization and impaired TLR function in the older indi-
viduals. In addition, fever, which is one of the cardinal signs
of inﬂuenza infection [35], may be absent or blunted 20%–
30% of the time in the aged population [36], thus, leading to
facilitated virus spreading.
2.2. Inﬂuenza Vaccine: A Vaccine Less Eﬀective in the Elderly
Than Previously Believed. The current trivalent inactivated
inﬂuenza vaccines (TIVs) contain 15μg of hemagglutinin
(HA) of each of the three strains (A/H1N1, A/H3N2, and
inﬂuenza B), stimulating a response in both B and Tcells,
resulting in humoral and cell-mediated immunity, respec-
tively [17, 37]. As depicted by Figure 2, vaccine antigens
are taken up by APCs, such as macrophages and dendritic
cells (DCs). The local innate immune response facilitates
maturation of DCs, which present stable major histocom-
patibility complex/peptide complexes. Mature DCs migrate
into regional lymph nodes, where they induce activation
and clonal expansion of naive CD4+ T-helper and CD8+Journal of Aging Research 3
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Figure 1: Schematic representation of the immune eﬀects of vitamin D: this ﬁgure depicts the principal innate and adaptive immune
responses to an antigenic challenge and the inﬂuence of vitamin D (positive regulation: increase or negative regulation: decrease) on these
responses (B cell: B lymphocyte, cyto T cell, cytotoxic T cell, DC: dendritic cell, MΦ: macrophage T cell: T lymphocyte; TLR: toll-like
receptor; TH: helper T cell; Treg: regulatory T cell; IL: interleukin; TNF: tumor necrosis factor; and INF: interferon).
cytotoxic T cells. The activation and diﬀerentiation of naive
B cells is induced by antigen and CD4+ T-helper cells.
Naive B cells diﬀerentiate into memory B cells and antibody-
secreting B cells. Long-term immunity is assured by memory
B and T cells in the blood and lymph nodes, as well as
by long-lived plasma cells and memory T cells in the bone
marrow.TIVsareconsideredasbotheﬀectiveandcostsaving
in preventing inﬂuenza infection in the aged population
[18, 19]. However, in spite of widespread application of
immunizationprogrammes,ratesofhospitalizationforacute
respiratory illness and cardiovascular disease have been in-
creased in population aged over 65 years during the annual
inﬂuenza seasons [18, 19]. Thus, vaccine eﬀectiveness,
deﬁned as the reduction in attack rates between vaccinated
and unvaccinated population, expected to be between 70
and 90% in younger adults is considerably reduced to less
than 40% over the age of 65 years [19]. This inability of
the immune system to amount an eﬀective response results
fromamultitudeofchangesoccurringintheimmunesystem
when we age. These changes are evident both in the innate
immunity and in the adaptive immune system [38, 39]. The
cumulative of a life-long reshaping and adaptation of the
immune system, in response to exposure to a plethora of
pathogenic challenges [40], cellular and molecular changes
[41–43], as well as thymic involution [44], is believed to
resultinthisdysfunctionalimmunity.However,failureofthe
immune system to provide protection to the body faced with
inﬂuenza antigen is not only related to immunosenescence
[38], but factors such as chronic comorbid conditions [45,
46], nutritional status [47, 48], and hormonal pathway
dysregulation [49, 50] seem to be important contributory
f a c t o r sa sw e l l[ 46].
3. IsVitDaPotentialImmune-EnhancingAgent
againstInﬂuenza?
In order to enhance the immune response and make the
ageing body more prone to protect itself from inﬂuenza
virus, novel vaccine designs and immunological therapeutic
approaches have been developed [19]. Whether modestly
increased immunogenicity was measured when administrat-
ing new adjuvanted, intradermal, or high-dose vaccines,
slightly higher side eﬀects have led to lower acceptability
[51].Strategiesreachingthegoalofrejuvenatingtheimmune
system and usually mentioned as the 3R’s of rejuvenation
(restoration, replacement, and reprogramming) [43]h a v e
been mainly achieved in experimental systems. However, no
clinical translation of these results is currently available [52],
except strategies using nutrients and protein-energy sup-
plements that included VitD as well [12, 53, 54].
3.1. Does VitD Have an Anti-Infectious Eﬀect?
Recently, there has been a great deal of interest in the role
played by VitD in host resistance to infection, and a number
of scientiﬁc claims reported broad anti-infectious eﬀects,
potentially beneﬁcial in people infected with inﬂuenza [13,
55, 56]. This emerging role of VitD in innate immunity
results in two ﬁndings: the immune system is able to produce4 Journal of Aging Research
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Figure 2: The normal immune response following inﬂuenza vaccination. Administration of vaccine antigens induces the activation of the
innate immune responses at the site of injection. The antigen is taken up by antigen-presenting cells (1), such as macrophages and dendritic
cells(DCs).ThelocalinnateimmuneresponsefacilitatesmaturationofDCs,whichpresentstablemajorhistocompatibilitycomplex/peptide
complexes (2). Mature DCs migrate into lymph nodes (3), where they induce activation and clonal expansion of naive CD4+ (4) and CD8+
(5) T cells. The activation and diﬀerentiation of naive B cells is induced by antigen and CD4+ T helper cells (6). Naive B cells diﬀerentiate
into memory B cells and antibody-secreting B cells (7). Long-term immunity is assured by memory B and T cells in the blood and lymph
nodes, as well as by long-lived plasma cells and memory T cells in the bone marrow (adapted from [17]).
1α-hydroxylase, the enzyme that converts circulating VitD
t oi t sa c t i v ef o r m[ 57–60] and the active VitD produced in
the immune system led to the production and regulation of
antimicrobial peptides such as cathelicidin and defensin β2
[13,61]whichinturninhibitedreplicationofMycobacterium
tuberculosis, in vitro [62]. However, recent randomized
controlled trials using VitD supplementation (3 doses of
100.000UI) showed no beneﬁcial eﬀect in clinical outcomes
or mortality in tuberculosis [63] while a meta-analysis
demonstrated a positive association between VDR polymor-
phisms with risk of tuberculosis [64]. Even though the latter
supported the hypothesis that VitD deﬁciency might play a
role as a risk factor during the development of tuberculosis,
another report in dialysis patients showed no association
between VitD supplementation and decreased risk of the
infection [65]. Evidence that VitD aﬀects clearance of
selected infections is also supported by epidemiological data
showing an inverted association between serum 25(OH)D
level and upper respiratory tract infection incidence rates
[6, 66]. This eﬀect was attributed to VitD regulation of
antimicrobial peptides such as cathelicidin [61]. In humans,
the only known cathelicidin is hCAP-18. It enhances micro-
bial killing in phagocytic vacuoles, acts as chemoattractant
for neutrophils and monocytes, and has a deﬁned VitD-
dependent mechanism [67, 68]. As depicted by Figure 1,
pathogenic antigens interact with TLRs on macrophages to
upregulatetheexpressionofgenesthatcodefortheVDRand
the 1α-hydroxylase enzyme [62, 69, 70]. In turn, the biolog-
ically active 1,25(OH)2D enhances cathelicidin synthesis by
interactingwiththepromoterofthehCAP-18[71–73].How-
ever, in order to activate hCAP-18 and enhance macrophage
f u n c t i o n ,i ti sn e c e s s a r yt or e a c hs u ﬃc i e n tl e v e l so ft h e
circulating form of VitD [6, 62, 73]. Thus, serum 25(OH)D
level of 30ng/mL (i.e., 75nmol/L) or more is necessary
for the optimal induction of cathelicidin messenger RNA.
Interestingly, higher levels (40ng/mL or 100nmol/L) do not
provide additional beneﬁt [6]. Thus, some hypothesized
that wintertime VitD insuﬃciency may explain seasonal
variation in inﬂuenza infection [61]. Whilst many reports
demonstrated the eﬀect of vitamin D on the increasedJournal of Aging Research 5
expression of antimicrobial peptides [13, 61, 74], the eﬀect
of either VitD or 1,25(OH)2D on these speciﬁc pep-
tides against inﬂuenza infection has not been tested in vitro
nor in vivo [13]. All together these ﬁndings demonstrate that
it is still diﬃcult to predict what the exact eﬀect of VitD
would be on host resistance to inﬂuenza virus.
3.2. How Could Vitamin D Modulate Inﬂuenza
Vaccine Immunogenicity?
Recent studies have demonstrated potent eﬀects of VitD on
cytokine production and in regulating normal innate and
adaptive immune functions in animals and humans [13–
16]. Indeed, as shown in Figure 1, the immunomodulatory
eﬀects of VitD are thought to be mediated via (i) its action
on APCs with the most potent reported eﬀects on DCs
[75–77], (ii) T-cell proliferation and cytokine production
with inhibition of the Th1-like cytokines (interleukin (IL)2,
IFNγ), increase of the Th2-like cytokines (IL4, IL5, IL10 and
IL13) and of the Th17-like cytokine (IL17) [78, 79], and (iii)
through direct eﬀects on B-cell homeostasis, proliferation,
and immunoglobulin production [80, 81]. Potential eﬀects
on a fourth group of CD4+ T cells exerting suppressor
rather than eﬀector functions and known as regulatory
T cells or Tregs have been also suspected [82–85]. As a
result, VitD coadministrated with TIV in mice was shown
to enhance the anti-HA antibody response and mucosal
immunity [86]. In humans, no signiﬁcant diﬀerence in HA
inhibition titers was detected in a randomized controlled
study conducted in healthy volunteers ranging in age from
18 to 49 years, vaccinated with TIV, and randomized for
1,25(OH)2D or placebo [54]. Three important limitations to
the conclusion are, however, drawn from this study. First,
the subjects in this study were young and healthy, and,
because their serum 25(OH)D level at baseline was not
measured, we can easily consider that these individuals were
not VitD deﬁcient. Second, signiﬁcant prevaccination HA
titers were measured in nearly all subjects. This indicates that
the subject had considerable immunity to the three vaccine
inﬂuenza strains before their vaccination. Since a clear
inverse relationship exists between preimmunization serum
HA antibody levels and antibody increase after vaccination,
this could have masked the potential immunomodulatory
eﬀect of VitD [19]. Third, vitamin supplementation and
vaccine were simultaneously injected. Even if the study used
the active form of VitD, the delay between the two injections
was too limited to expect any beneﬁcial biological eﬀects
on B and T cells or on components of innate immunity.
More recently, Chadha et al. investigated the inﬂuence of
baselineserum25(OH)DlevelonserologicalresponsetoTIV
vaccination [53]. While the results demonstrated that there
was a signiﬁcant eﬀect of baseline 25(OH)D when tested
as a continuous variable in relation to serological response,
the study conclusions were also aﬀected by three important
limitations. First, subjects enrolled in the study were only
men with cancer, a comorbid condition well known by itself
as limiting immune system capacities. Second, at baseline
a large number of patients were taking high dose of VitD
with a median dose of 2000IU/day (dose range from 800 to
9.000UI). Enrolled subjects had median 25(OH)D level of
44.88ng/mL (i.e., 112.2nmol/L), much higher than values
usually found in most cancer patients population (i.e., 22-
23ng/mL or 55–58nmol/L) [87]. Third, the small sample
size of 60 subjects has probably underpowered the study
design. While the beneﬁcial eﬀect observed only with the
A/H3N2 strain correlated with previous ﬁndings from a
randomized controlled trial of VitD supplementation versus
placebo in school children [88]; responses to individual
strains of inﬂuenza vaccine among patients with lowest and
h i g h e s tq u a r t i l eo f2 5 ( O H ) Dl e v e lw e r en o td i ﬀerent for
A/H1N1 and B strains. Also, when any virus strains were
considered, the diﬀerence between the vaccine response rates
were insigniﬁcant, despite a 30% diﬀerence between the two
groups.
Finally, similar to potential antimicrobial eﬀects of VitD,
more evidence is still needed in humans in order to de-
termine if there is a true causal link between changes in
VitD and immune system regulation. Continued evaluation
oftheconsequencesofVitDinsuﬃciencyappearswarranted.
Future studies should address the question whether VitD
supplementation enhances immune response to inﬂuenza
vaccination in nonsupplemented population with low base-
line serum 25(OH) levels and thus preventing inﬂuenza
clinical outcomes.
4. Conclusion
Inﬂuenza infection remains a major public health concern
across the world. The overall body of evidence suggests that
older adults are more prone to be infected by inﬂuenza
virus. While inﬂuenza prevention strategies are mainly based
on immunization, current inﬂuenza vaccines do not oﬀer
optimal protection in this population due, in part, to waning
immunity. Even if VitD has profound eﬀects on immunity
and clinical and epidemiological data suggest that VitD
insuﬃciency increases susceptibility to inﬂuenza infection,
there is not yet suﬃcient information to clarify the true
relationship between VitD status and host resistance or
inﬂuenzavaccineimmunogenicity.Itis,therefore,premature
at this time to recommend “booster” VitD supplementations
at the beginning of annual inﬂuenza seasons in order
to prevent infection in the elderly population. However,
assessing VitD status and maintaining optimal serum levels
should be considered in all ageing and old adults in order to
prevent bone and promote healthy ageing.
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